Jeremy Gowler is recorded as CEO and COO at Invivyd, Inc. (IVVD). The newest filing on record that lists Jeremy Gowler as CEO at Invivyd, Inc. (IVVD) is dated April 18, 2024. The newest filing on record that lists Jeremy Gowler as COO at Invivyd, Inc. (IVVD) is dated April 10, 2023. Invivyd, Inc. reported in an 8-K filed April 12, 2024 that Jeremy Gowler was appointed Interim Chief Executive Officer, effective April 11, 2024. Invivyd, Inc. reported in an 8-K filed December 6, 2022 that Jeremy Gowler was appointed Chief Operating Officer and Chief Commercial Officer, effective December 16, 2022. The proxy statement of Invivyd, Inc. reports total compensation of $605,382 for Jeremy Gowler in fiscal 2024, including a base salary of $245,692. Disclosed compensation is on record for 2 fiscal years. Jeremy Gowler has spoken on 1 earnings call across 1 company, most recently for Invivyd, Inc. on May 9, 2024. Invivyd, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Invivyd, Inc. includes Marc Elia (CEO and Board Member), William Duke, Jr. (CEO), Frederick W. Driscoll (CFO) and 7 others.
“On April 11, 2024, the Board appointed Jeremy Gowler, the Company's current Chief Operating Officer and Chief Commercial Officer, as the Company's Interim Chief Executive Officer and designated him as the Company's "principal executive officer", effective immediately.”
Invivyd, Inc. Form 8-K, filed April 12, 2024
· Read the filing
“On December 6, 2022, Invivyd, Inc. (the “Company”) announced the appointment of Jeremy Gowler, age 46, as the Company’s Chief Operating Officer and Chief Commercial Officer, effective as of December 16, 2022 (the “Gowler Effective Date”).”
Invivyd, Inc. Form 8-K, filed December 6, 2022
· Read the filing
Jeremy Gowler on recent calls
“PEMGARDA is a high-value medicine for moderately to severely immunocompromised individuals who are in urgent need of protection from COVID-19. It fills a critical need not otherwise addressed in the marketplace today.”
